Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Reconsidering pluripotency tests: do we still need teratoma assays?

Buta C, David R, Dressel R, Emgård M, Fuchs C, Gross U, Healy L, Hescheler J, Kolar R, Martin U, Mikkers H, Müller FJ, Schneider RK, Seiler AE, Spielmann H, Weitzer G.

Stem Cell Res. 2013 Jul;11(1):552-62. doi: 10.1016/j.scr.2013.03.001. Review.

2.

Teratoma: from spontaneous tumors to the pluripotency/malignancy assay.

Bulic-Jakus F, Katusic Bojanac A, Juric-Lekic G, Vlahovic M, Sincic N.

Wiley Interdiscip Rev Dev Biol. 2016 Mar-Apr;5(2):186-209. doi: 10.1002/wdev.219. Review.

PMID:
26698368
3.

A call to standardize teratoma assays used to define human pluripotent cell lines.

Müller FJ, Goldmann J, Löser P, Loring JF.

Cell Stem Cell. 2010 May 7;6(5):412-4. doi: 10.1016/j.stem.2010.04.009.

4.

Standardization of the teratoma assay for analysis of pluripotency of human ES cells and biosafety of their differentiated progeny.

Gropp M, Shilo V, Vainer G, Gov M, Gil Y, Khaner H, Matzrafi L, Idelson M, Kopolovic J, Zak NB, Reubinoff BE.

PLoS One. 2012;7(9):e45532. doi: 10.1371/journal.pone.0045532.

5.

Teratoma formation of human embryonic stem cells in three-dimensional perfusion culture bioreactors.

Stachelscheid H, Wulf-Goldenberg A, Eckert K, Jensen J, Edsbagge J, Björquist P, Rivero M, Strehl R, Jozefczuk J, Prigione A, Adjaye J, Urbaniak T, Bussmann P, Zeilinger K, Gerlach JC.

J Tissue Eng Regen Med. 2013 Sep;7(9):729-41. doi: 10.1002/term.1467.

PMID:
22438087
6.

Experimental teratoma: at the crossroad of fetal- and onco-development.

Hultman I, Björk L, Blomberg E, Sandstedt B, Ahrlund-Richter L.

Semin Cancer Biol. 2014 Dec;29:75-9. doi: 10.1016/j.semcancer.2014.08.005. Review.

PMID:
25153353
7.

Teratoma generation in the testis capsule.

Peterson SE, Tran HT, Garitaonandia I, Han S, Nickey KS, Leonardo T, Laurent LC, Loring JF.

J Vis Exp. 2011 Nov 7;(57):e3177. doi: 10.3791/3177.

8.

Teratoma formation: a tool for monitoring pluripotency in stem cell research.

Nelakanti RV, Kooreman NG, Wu JC.

Curr Protoc Stem Cell Biol. 2015 Feb 2;32:4A.8.1-17. doi: 10.1002/9780470151808.sc04a08s32.

9.

A qPCR ScoreCard quantifies the differentiation potential of human pluripotent stem cells.

Tsankov AM, Akopian V, Pop R, Chetty S, Gifford CA, Daheron L, Tsankova NM, Meissner A.

Nat Biotechnol. 2015 Nov;33(11):1182-92. doi: 10.1038/nbt.3387.

10.

Functional assays for human embryonic stem cell pluripotency.

O'Connor MD, Kardel MD, Eaves CJ.

Methods Mol Biol. 2011;690:67-80. doi: 10.1007/978-1-60761-962-8_4.

PMID:
21042985
11.

Apoptotic susceptibility to DNA damage of pluripotent stem cells facilitates pharmacologic purging of teratoma risk.

Smith AJ, Nelson NG, Oommen S, Hartjes KA, Folmes CD, Terzic A, Nelson TJ.

Stem Cells Transl Med. 2012 Oct;1(10):709-18. doi: 10.5966/sctm.2012-0066.

12.

Putting stem cells to the test.

Dolgin E.

Nat Med. 2010 Dec;16(12):1354-7. doi: 10.1038/nm1210-1354. No abstract available.

PMID:
21135828
13.

Monkey embryonic stem cell lines expressing green fluorescent protein.

Takada T, Suzuki Y, Kondo Y, Kadota N, Kobayashi K, Nito S, Kimura H, Torii R.

Cell Transplant. 2002;11(7):631-5.

PMID:
12518890
14.

Identification of unsafe human induced pluripotent stem cell lines using a robust surrogate assay for pluripotency.

Polanco JC, Ho MS, Wang B, Zhou Q, Wolvetang E, Mason E, Wells CA, Kolle G, Grimmond SM, Bertoncello I, O'Brien C, Laslett AL.

Stem Cells. 2013 Aug;31(8):1498-510. doi: 10.1002/stem.1425.

15.

Testicular teratomas: an intersection of pluripotency, differentiation and cancer biology.

Bustamante-Marín X, Garness JA, Capel B.

Int J Dev Biol. 2013;57(2-4):201-10. doi: 10.1387/ijdb.130136bc. Review.

16.

Characterizing Pluripotent Stem Cells Using the TaqMan® hPSC Scorecard(TM) Panel.

Fergus J, Quintanilla R, Lakshmipathy U.

Methods Mol Biol. 2016;1307:25-37. doi: 10.1007/7651_2014_109.

PMID:
25138722
17.

Generation and characterization of human induced pluripotent stem cells.

Ohnuki M, Takahashi K, Yamanaka S.

Curr Protoc Stem Cell Biol. 2009 Jun;Chapter 4:Unit 4A.2. doi: 10.1002/9780470151808.sc04a02s9.

PMID:
19536759
18.

STB-HO, a novel mica fine particle, inhibits the teratoma-forming ability of human embryonic stem cells after in vivo transplantation.

Choi SW, Shin TH, Uddin MH, Shin JH, Kang TW, Lee BC, Kim HS, Seo Y, Shams S, Jung YK, Kang KS.

Oncotarget. 2016 Jan 19;7(3):2684-95. doi: 10.18632/oncotarget.6472.

19.

The teratoma assay: an in vivo assessment of pluripotency.

Wesselschmidt RL.

Methods Mol Biol. 2011;767:231-41. doi: 10.1007/978-1-61779-201-4_17.

PMID:
21822879
20.

Analysis of embryoid bodies derived from human induced pluripotent stem cells as a means to assess pluripotency.

Sheridan SD, Surampudi V, Rao RR.

Stem Cells Int. 2012;2012:738910. doi: 10.1155/2012/738910.

Supplemental Content

Support Center